{
    "nct_id": "NCT03745287",
    "official_title": "A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell Disease",
    "inclusion_criteria": "* Diagnosis of severe sickle cell disease as defined by:\n* Documented severe sickle cell disease genotype\n* History of at least two severe vaso-occlusive crisis events per year for the previous two years prior to enrollment\n* Eligible for autologous stem cell transplant as per investigators judgment\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 12 Years\nMust have maximum age of 35 Years",
    "exclusion_criteria": "* An available 10/10 human leukocyte antigen (HLA)-matched related donor\n* Prior hematopoietic stem cell transplant (HSCT)\n* Clinically significant and active bacterial, viral, fungal, or parasitic infection\n\nOther protocol defined inclusion/exclusion criteria may apply",
    "miscellaneous_criteria": "Key"
}